The company's Q2 revenues were up less than 1 percent from $596.2 million in Q2 2018, and short of the average Wall Street estimate of $601.4 million.
The firms will use Biodesix's biomarker discovery platform to analyze the proteome of pancreatic cancer patients treated with Immodulon's immunotherapy IMM-101.
In a recent study, the researchers used the software to analyze multi-omic ovarian cancer data generated by the TCGA and CPTAC initiatives.
The firm will use the proceeds to continue developing its Proteograph platform, build its proteomic database, and develop liquid biopsy products for early disease detection.
The study, which used DIA mass spec to analyze 96 patient samples, demonstrates the accessibility of current proteomic technology, said one of its authors.
EdiGene has developed a diploid library of 2,800 single clonal knockout cell lines, targeting 2,600 genes in commonly used human cancer cell lines.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
The deals cover Native Antigen's native and recombinant viral and bacterial antigens, antibodies, and immunoassays in certain European and Asian markets.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
At the recent ASMS annual meeting, vendors including Bruker, Sciex, and Thermo Fisher Scientific presented new versions of the fast-growing mass spec technique.
The company develops assays and reagents for tissue-based biomarker research and discovery including its UltiMapper line of multiplexed assays.
Quanterix said that the acquisition will secure the supply of neurofilament light antibodies that are critical to its Simoa assays and services.
The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
The company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.
The agreement follows a number of other distribution deals Bioké has signed in recent months including ones with Omni Life Science, Syntec, and Namocell.
New instrumentation, reagents, and methods, as well as increasing interest in small and single-cell samples, could prove a boon for the technology.
The Singapore-based firm plans to use its single-cell RNA and protein assay to help optimize the production of CAR T cells and guide their use in patients.
New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
A recent pair of papers presenting deep learning approaches to mass spec proteomic data analysis build on several previous efforts to develop such methods.
The company sold 2.2 million shares at an average price of $22.73 per share under a $50 million at-the-market equity facility it filed in March 2019.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.